CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
CRISPR biosensors enable real-time health monitoring with attomolar sensitivity, wearable integration, and multiplex ...
Morning Overview on MSN
CRISPR researchers revived an ancient gene that could block disease
Researchers have used CRISPR to switch back on a gene that vanished from the human lineage roughly 20 million years ago, ...
Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...
Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...
Opinion
4dOpinion
A precise tool to edit life: How CRISPR genome editing is changing agriculture and healthcare
Imagine if you could fix a spelling mistake in a long document with just one click. Now, imagine doing the same with the genetic code of a plant or even a human cell. That’s ...
While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...
These companies could innovate their way to success.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results